ECSP024375A - Derivados del 2-aminotiazolina y sus uso como inhibidores de no sintetasa - Google Patents

Derivados del 2-aminotiazolina y sus uso como inhibidores de no sintetasa

Info

Publication number
ECSP024375A
ECSP024375A EC2002004375A ECSP024375A ECSP024375A EC SP024375 A ECSP024375 A EC SP024375A EC 2002004375 A EC2002004375 A EC 2002004375A EC SP024375 A ECSP024375 A EC SP024375A EC SP024375 A ECSP024375 A EC SP024375A
Authority
EC
Ecuador
Prior art keywords
radical
pyridyl
derivatives
inhibitors
alkyl radical
Prior art date
Application number
EC2002004375A
Other languages
English (en)
Inventor
Dominique Damour
Jean-Christophe Carry
Erick Bacque
Antony Bigot
Michel Tabart
Serge Mignani
Claude Guyon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ECSP024375A publication Critical patent/ECSP024375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

El presente invento se refiere a los derivados de 2- aminotiazolina de fórmula (1) en donde R1 es un átomo de hidrógeno o un radical alquilo y R2 es un radical alquilo, alk-NH2, -CH-R3, CH2-S-R4 o fenilo sustituido por un radical nitro o -NH-C(NH)CH3, es decir R1 es un radical alquilo y R2 es un átomo de hidrógeno, R3 es un radical cicloalquilo (3-6C), piridilo, N-oxido de piridilo, thienilo, tiazolilo, imidazolilo, pirazinilo, triazolilo, fenilo o fenilo sustituido por un radical nitro, hidroxi o carboxi, R4 representa un radical pyridilo o N-oxido de piridilo, alk representa un radical alquileno o sus sales farmacéuticamente aceptables con excepción de ciertos compuestos conocidos y el uso de estos derivados como inhibidores de la NO-sintetasa inducible.
EC2002004375A 2000-06-09 2002-12-09 Derivados del 2-aminotiazolina y sus uso como inhibidores de no sintetasa ECSP024375A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0007397A FR2810037B1 (fr) 2000-06-09 2000-06-09 Utilisation de derives de 2-aminothiazoline comme inhibiteurs de no-synthase inductible

Publications (1)

Publication Number Publication Date
ECSP024375A true ECSP024375A (es) 2003-02-06

Family

ID=8851134

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004375A ECSP024375A (es) 2000-06-09 2002-12-09 Derivados del 2-aminotiazolina y sus uso como inhibidores de no sintetasa

Country Status (29)

Country Link
EP (1) EP1299365B1 (es)
JP (1) JP4238026B2 (es)
KR (1) KR20030025931A (es)
CN (1) CN1202096C (es)
AP (1) AP2002002708A0 (es)
AR (1) AR029937A1 (es)
AT (1) ATE305460T1 (es)
AU (1) AU2001266124A1 (es)
BR (1) BR0111986A (es)
CA (1) CA2411760C (es)
DE (1) DE60113689T2 (es)
DK (1) DK1299365T3 (es)
DZ (1) DZ3367A1 (es)
EA (1) EA200300010A1 (es)
EC (1) ECSP024375A (es)
ES (1) ES2248347T3 (es)
FR (1) FR2810037B1 (es)
HK (1) HK1057900A1 (es)
HR (1) HRP20020970A2 (es)
HU (1) HUP0301000A2 (es)
IL (1) IL153328A0 (es)
MA (1) MA25814A1 (es)
MX (1) MXPA02012071A (es)
NO (1) NO20025884L (es)
NZ (1) NZ522968A (es)
OA (1) OA12286A (es)
PL (1) PL360285A1 (es)
WO (1) WO2001094325A1 (es)
ZA (1) ZA200209769B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140964D1 (en) * 2001-09-26 2010-02-11 Yissum Res Dev Co Sphingolipiden
CA2465691C (fr) * 2001-11-09 2011-07-19 Aventis Pharma S.A. Derives de 2-amino-4-heteroarylethyl thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
DE60234117D1 (de) * 2001-11-09 2009-12-03 Aventis Pharma Sa 2-amino-4-pyridylmethyl-thiazolinderivate und ihre verwendung als induzierbare no-synthase inhibitoren
PL370324A1 (en) * 2001-11-09 2005-05-16 Aventis Pharma S.A. 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
AU2002238889A1 (en) * 2002-03-14 2003-09-22 Dainippon Pharmaceutical Co., Ltd. Nitrogen monoxide synthase inhibitors
CA2494323C (en) * 2002-08-07 2011-01-25 Neuraxon Inc. Amino benzothiazole compounds with nos inhibitory activity
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen
KR101800507B1 (ko) 2015-09-18 2018-01-18 주식회사 이엔이티아이 자동세척 스크린과 식물정화장치를 활용하여 지속적으로 유입되는 생활하수나 공정폐수가 유입되는 오염하천정화를 위한 방법 및 그 장치

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066662A (en) * 1990-05-21 1991-11-19 Warner-Lambert Company Substituted oxazolidin-2-ones and 1,2,4-oxadiazolin-5-ones and derivatives thereof acting at muscarinic receptors
SI9300616A (en) * 1992-11-27 1994-06-30 Wellcome Found Enzyme inhibitors
CA2173468A1 (en) * 1993-10-21 1995-04-27 Donald W. Hansen, Jr. Amidino derivatives useful as nitric oxide synthase inhibitors
AU4149696A (en) * 1994-11-15 1996-06-06 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives

Also Published As

Publication number Publication date
NO20025884D0 (no) 2002-12-06
IL153328A0 (en) 2003-07-06
JP4238026B2 (ja) 2009-03-11
DE60113689D1 (de) 2006-02-09
FR2810037A1 (fr) 2001-12-14
AR029937A1 (es) 2003-07-23
KR20030025931A (ko) 2003-03-29
DK1299365T3 (da) 2006-02-06
AU2001266124A1 (en) 2001-12-17
EA200300010A1 (ru) 2003-06-26
NO20025884L (no) 2003-01-29
EP1299365A1 (fr) 2003-04-09
HRP20020970A2 (en) 2005-02-28
NZ522968A (en) 2005-07-29
ZA200209769B (en) 2004-03-02
MXPA02012071A (es) 2004-09-10
DE60113689T2 (de) 2006-07-13
ES2248347T3 (es) 2006-03-16
CN1444572A (zh) 2003-09-24
AP2002002708A0 (en) 2002-12-31
JP2003535853A (ja) 2003-12-02
BR0111986A (pt) 2003-04-01
EP1299365B1 (fr) 2005-09-28
PL360285A1 (en) 2004-09-06
HK1057900A1 (en) 2004-04-23
CA2411760C (fr) 2009-12-29
FR2810037B1 (fr) 2004-04-23
HUP0301000A2 (hu) 2003-08-28
CA2411760A1 (fr) 2001-12-13
ATE305460T1 (de) 2005-10-15
DZ3367A1 (fr) 2001-12-13
CN1202096C (zh) 2005-05-18
OA12286A (en) 2006-05-12
WO2001094325A1 (fr) 2001-12-13
MA25814A1 (fr) 2003-07-01

Similar Documents

Publication Publication Date Title
NO20054856D0 (no) 4-anilo-kinazolinderivater som antiproliferative midler
AR068813A1 (es) Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata
ES2182535T3 (es) Derivados de benzo(b)tiepina-1,-dioxido, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
TW200716576A (en) Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
NO20073956L (no) Pyrazolderivater for inhibering av CDK og GSK
TW200642683A (en) Heterocyclic compound
CY1114083T1 (el) Συνδυασμος μιας ενωσης της 5-φαινυλοθειαζολης ως αναστολεας της κινασης pi3 με ενα αντιφλεγμονωδες, βρογχοδιασταλτικο ή αντιισταμινικο φαρμακo
DOP2010000046A (es) Compuestos de biciclolactama sustituida
CY1107677T1 (el) Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine
CO4700453A1 (es) N-(INDOL-2-CARBONIL)-beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO AGENTES ANTIDIABETICOS
DOP2006000045A (es) Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica
TW200613297A (en) Pyrazole derivatives
MX2010000658A (es) Derivados de pirimidina 934.
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
PE20201068A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos
ECSP024375A (es) Derivados del 2-aminotiazolina y sus uso como inhibidores de no sintetasa
CO5680420A2 (es) Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4
MX2016003630A (es) Compuestos heterociclicos de n-acilimino.
AR045326A1 (es) Derivados de aminoquinolina y su uso como ligandos a3 de adenosina
MY137964A (en) Benzofuran derivative